1068,38 €
1187,09 €
-10% with code: EXTRA
Pharmaceutical Biocatalysis
Pharmaceutical Biocatalysis
1068,38
1187,09 €
  • We will send in 10–14 business days.
This book provides an overview of the world market of therapeutic enzymes and enzyme inhibitors, rare diseases, orphan drugs, the costs of drug development and therapies, and enzymes in downstream processing of pharmaceuticals. It discusses carbonic anhydrase inhibitors and their multiple drug interactions, carboxylesterase inhibitors for pharmaceutical applications, employment of inhibitors for the treatment of neurodegenerative diseases, use of engineered proteins, bioactive peptides, and fib…
  • Publisher:
  • Year: 2019
  • Pages: 1000
  • ISBN-10: 9814800619
  • ISBN-13: 9789814800617
  • Format: 15.8 x 23.1 x 4.3 cm, hardcover
  • Language: English
  • SAVE -10% with code: EXTRA

Pharmaceutical Biocatalysis (e-book) (used book) | bookbook.eu

Reviews

Description

This book provides an overview of the world market of therapeutic enzymes and enzyme inhibitors, rare diseases, orphan drugs, the costs of drug development and therapies, and enzymes in downstream processing of pharmaceuticals. It discusses carbonic anhydrase inhibitors and their multiple drug interactions, carboxylesterase inhibitors for pharmaceutical applications, employment of inhibitors for the treatment of neurodegenerative diseases, use of engineered proteins, bioactive peptides, and fibrinolytic enzymes for thrombolytic therapy, and enzymes important for the design and development of new drugs/drug metabolites such as aldehyde oxidases and cytochrome P450 enzymes and the role the latter play in vascular biology and pathophysiology. The treatment of cancer is explored in connection with enzymatic amino acid deprivation therapies and new drugs that act as chemical degraders of oncogenic proteins. The book also introduces the resistance mechanisms of cancer. Furthermore, it provides an insight into the relationship between pathological conditions of cardiovascular disease and oxidative stress. The text also focuses on the potential use of nanoparticles as carriers for enzymes with medical relevance, computer-aided drug design for the identification of multi-target directed ligands, and the development of improved therapeutics through a glycan-"designer" approach. It concludes with an introduction to the chemoenzymatic synthesis of drugs.

EXTRA 10 % discount with code: EXTRA

1068,38
1187,09 €
We will send in 10–14 business days.

The promotion ends in 18d.19:04:29

The discount code is valid when purchasing from 10 €. Discounts do not stack.

Log in and for this item
you will receive 11,87 Book Euros!?
  • Publisher:
  • Year: 2019
  • Pages: 1000
  • ISBN-10: 9814800619
  • ISBN-13: 9789814800617
  • Format: 15.8 x 23.1 x 4.3 cm, hardcover
  • Language: English English

This book provides an overview of the world market of therapeutic enzymes and enzyme inhibitors, rare diseases, orphan drugs, the costs of drug development and therapies, and enzymes in downstream processing of pharmaceuticals. It discusses carbonic anhydrase inhibitors and their multiple drug interactions, carboxylesterase inhibitors for pharmaceutical applications, employment of inhibitors for the treatment of neurodegenerative diseases, use of engineered proteins, bioactive peptides, and fibrinolytic enzymes for thrombolytic therapy, and enzymes important for the design and development of new drugs/drug metabolites such as aldehyde oxidases and cytochrome P450 enzymes and the role the latter play in vascular biology and pathophysiology. The treatment of cancer is explored in connection with enzymatic amino acid deprivation therapies and new drugs that act as chemical degraders of oncogenic proteins. The book also introduces the resistance mechanisms of cancer. Furthermore, it provides an insight into the relationship between pathological conditions of cardiovascular disease and oxidative stress. The text also focuses on the potential use of nanoparticles as carriers for enzymes with medical relevance, computer-aided drug design for the identification of multi-target directed ligands, and the development of improved therapeutics through a glycan-"designer" approach. It concludes with an introduction to the chemoenzymatic synthesis of drugs.

Reviews

  • No reviews
0 customers have rated this item.
5
0%
4
0%
3
0%
2
0%
1
0%
(will not be displayed)